Confirmatory Study of DSP-5423P in Patients With Schizophrenia
Phase of Trial: Phase III
Latest Information Update: 27 Mar 2017
At a glance
- Drugs Blonanserin (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 21 Jul 2016 Planned primary completion date changed from 1 Apr 2018 to 1 Dec 2018.
- 08 Jul 2016 Planned number of patients changed from 360 to 501.
- 01 Feb 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.